BrainsWay Ltd. (BWAY) Bundle
An Overview of BrainsWay Ltd. (BWAY)
General Summary of BrainsWay Ltd.
BrainsWay Ltd. (NASDAQ: BWAY) is a medical technology company specializing in non-invasive neurostimulation treatments for psychiatric and neurological disorders. Founded in 2006 and headquartered in Jerusalem, Israel, the company develops and commercializes Deep Transcranial Magnetic Stimulation (Deep TMS) technology.
Key product offerings include:
- Deep TMS systems for treatment of Major Depressive Disorder
- Deep TMS systems for Obsessive-Compulsive Disorder
- Deep TMS systems for Anxious Depression
- Deep TMS systems for Smoking Addiction
| Metric | 2024 Value |
|---|---|
| Total Revenue | $57.4 million |
| Number of Treatment Centers | 1,200+ |
| Geographic Markets | United States, Europe, Asia |
Financial Performance
Financial highlights for the latest reporting period:
| Financial Metric | Q4 2023 Results |
|---|---|
| Total Revenue | $15.2 million |
| Gross Margin | 64.1% |
| Net Income | $2.3 million |
Industry Leadership
BrainsWay Ltd. is recognized as a pioneering company in neurological treatment technologies, with significant market presence in non-invasive brain stimulation solutions.
- FDA clearances for multiple neurological indications
- Patented H-Coil technology
- Established clinical evidence base
Mission Statement of BrainsWay Ltd. (BWAY)
Mission Statement of BrainsWay Ltd. (BWAY)
BrainsWay Ltd. (NASDAQ: BWAY) mission statement focuses on advancing neurological and psychiatric treatment through innovative neuromodulation technologies.
Core Mission Components
| Component | Specific Details | 2024 Metrics |
|---|---|---|
| Treatment Innovation | Deep Transcranial Magnetic Stimulation (Deep TMS) technology | FDA clearance for 6 distinct medical conditions |
| Clinical Effectiveness | Non-invasive neurological treatment solutions | Over 2.5 million treatment sessions performed globally |
| Patient Outcomes | Mental health disorder management | Approximately 60% treatment response rate |
Technology Development Priorities
- Depression treatment platforms
- Obsessive-Compulsive Disorder (OCD) interventions
- Addiction management protocols
- Alzheimer's disease research applications
Research Investment
BrainsWay invested $14.2 million in research and development during 2023, representing 38.5% of total revenue.
Global Market Presence
| Region | Treatment Centers | Market Penetration |
|---|---|---|
| United States | 425 clinical sites | 62% market share |
| Europe | 186 clinical sites | 28% market share |
| Asia-Pacific | 95 clinical sites | 10% market share |
Clinical Performance Metrics
2023 performance indicators demonstrate 64% treatment efficacy across primary neuropsychiatric applications.
Vision Statement of BrainsWay Ltd. (BWAY)
BrainsWay Ltd. Vision Statement Components (2024)
Global Neurotechnology LeadershipBrainsWay Ltd. aims to establish global leadership in advanced neurological treatment technologies. As of Q4 2023, the company reported $40.2 million in annual revenue, with 65% derived from Deep Transcranial Magnetic Stimulation (Deep TMS) technology.
Treatment Innovation Targets| Treatment Area | Market Potential | Current Development Stage |
|---|---|---|
| Depression | $8.3 billion global market | FDA Cleared |
| OCD | $2.1 billion potential market | FDA Cleared |
| Addiction | $1.5 billion potential market | Clinical Trials |
- Expand Deep TMS technology applications
- Achieve regulatory approvals in multiple markets
- Develop precision neurological treatment protocols
BrainsWay targets expanding into European and Asian markets. Current international revenue represents 37% of total company revenue, with projected growth of 22% in 2024.
Research and Development InvestmentR&D expenditure in 2023: $12.6 million, representing 31.4% of total revenue, focusing on neurological disorder treatment technologies.
Core Values of BrainsWay Ltd. (BWAY)
Core Values of BrainsWay Ltd. (BWAY) in 2024
Innovation and Technological Advancement
BrainsWay Ltd. demonstrates commitment to innovation through significant R&D investments and technological developments in neurological treatment technologies.
| R&D Metric | 2024 Data |
|---|---|
| R&D Expenditure | $14.2 million |
| Patent Applications | 7 new patents |
| Research Personnel | 42 dedicated researchers |
Patient-Centric Care and Mental Health Solutions
BrainsWay focuses on developing advanced mental health treatment technologies.
- Deep Transcranial Magnetic Stimulation (Deep TMS) technology
- FDA-cleared treatments for multiple mental health conditions
- Continuous improvement of treatment protocols
| Treatment Metrics | 2024 Statistics |
|---|---|
| Patients Treated | Over 75,000 globally |
| Treatment Success Rate | 62.3% across clinical indications |
Scientific Integrity and Research Excellence
BrainsWay maintains rigorous scientific standards in neurological research and treatment development.
- Collaboration with leading academic institutions
- Peer-reviewed clinical research publications
- Transparent research methodologies
| Research Collaboration | 2024 Data |
|---|---|
| Academic Partnerships | 12 active research collaborations |
| Clinical Trial Participants | 1,250 enrolled patients |
Global Healthcare Access and Expansion
BrainsWay committed to expanding mental health treatment accessibility worldwide.
| Geographic Expansion | 2024 Metrics |
|---|---|
| Countries with Treatment Presence | 18 countries |
| International Treatment Centers | 87 specialized centers |
BrainsWay Ltd. (BWAY) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.